During the research by the institution on June 25th, Beijing Bohui Innovation (Stock Code 300318) stated that the overall supply of albumin is relatively stable, and due to factors such as the low season of albumin consumption from June to September, terminal demand has slightly declined. However, the overall supply and demand is in compliance with the market regulations. Due to the decrease of industry licenses issuance, the demand for CTP is at a relatively high level compared to other blood products. The company's indicator products can currently meet the use of existing customers and terminals, maintaining a balance of supply and demand.
博晖创新：受行业批签发下降影响 静丙需求处于较高水平
Beijing Bohui Innovation Biotechnology Group: Affected by the decrease of industry licenses issuance, demand for CTP is at a relatively high level.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.